Outlook Therapeutics expands in Europe while facing U.S. regulatory hurdles

Outlook Therapeutics is pushing ahead with its European expansion while dealing with setbacks in the U.S. The company has launched its ophthalmic drug LYTENAVA in Austria and plans further rollouts across Europe. Meanwhile, it is working to address regulatory hurdles for its drug ONS-5010 after an FDA rejection letter.

The company's European strategy is gaining momentum. In January 2026, LYTENAVA became available in Austria, with Ireland and the Netherlands set to follow later this year. By the end of 2027, the drug is expected to reach four more European countries: France, Italy, Spain, and Switzerland. A new exclusive distribution deal for Switzerland has already been signed.

Regulatory challenges remain in the U.S. The FDA rejected ONS-5010, prompting the company to request a Type A meeting for clarity on additional efficacy data. The outcome of this meeting will shape the drug's commercial future in America.

Key financial dates are also on the horizon. Shareholders will gather for the annual general meeting on March 10, 2026. Earnings reports are scheduled for May 13, 2026 (second quarter) and August 12, 2026 (third quarter).

The accelerated European launch of LYTENAVA aims to counterbalance delays in the U.S. market. With multiple country rollouts planned by 2027, the company is broadening its reach. The FDA's response to the Type A meeting will determine the next steps for ONS-5010 in the U.S.